Literature DB >> 22844353

IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma.

Hideyuki Suzuki1, Hitoshi Ogawa, Koh Miura, Sho Haneda, Kazuhiro Watanabe, Shinobu Ohnuma, Hiroyuki Sasaki, Tomohiko Sase, Shunichi Kimura, Taiki Kajiwara, Toshihiro Komura, Masahide Toshima, Yasufumi Matsuda, Chikashi Shibata, Iwao Sasaki.   

Abstract

Interleukin-23 (IL-23) plays an essential role in the mucosal immune system. It has been suggested that IL-23 is able to induce carcinogenesis as well as inflammation and a recent study revealed that IL-23R is expressed in colorectal carcinoma cells. However, neither the differences in the IL-23R expression among the patients nor the concrete functions of IL-23 in colorectal carcinoma cells have been revealed. The aim of the present study was to examine the characteristics of IL-23R expression in colorectal carcinoma and the direct effects of IL-23 on colorectal cancer cells. We examined the IL-23R expression in human colorectal cancer tissue samples by immunohistochemistry. Cell proliferation and invasion assays under IL-23 stimulation were performed using cultured cells derived from colorectal cancer. ELISA and real-time PCR were used to evaluate the transforming growth factor (TGF)-β production due to IL-23 stimulation. All of the TNM stage IV patients were positive for IL-23R. IL-23R expression in the carcinoma tissue was also relatively high at the deepest point of invasion in certain cases. The proliferative and invasive activities and/or TGF-β production of DLD-1 cells increased by IL-23 stimulation, whereas no change was observed in the activities of MIP101 and KM12c cells. IL-23 directly enhanced the malignancy of the colon carcinoma cells. An autocrine mechanism via TGF-β production may underlie these effects. IL-23 is therefore a potential target for cancer immunotherapy. However, the homogeneity in IL-23R expression and the effects of IL-23 on colorectal carcinoma cells should be considered.

Entities:  

Year:  2012        PMID: 22844353      PMCID: PMC3402724          DOI: 10.3892/ol.2012.739

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

Review 1.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

2.  IL-23 promotes tumour incidence and growth.

Authors:  John L Langowski; Xueqing Zhang; Lingling Wu; Jeanine D Mattson; Taiying Chen; Kathy Smith; Beth Basham; Terrill McClanahan; Robert A Kastelein; Martin Oft
Journal:  Nature       Date:  2006-05-10       Impact factor: 49.962

Review 3.  IL-23/IL-17 axis in IBD.

Authors:  Massimiliano Sarra; Francesco Pallone; Thomas T Macdonald; Giovanni Monteleone
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

4.  IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.

Authors:  David Yen; Jeanne Cheung; Heleen Scheerens; Frédérique Poulet; Terrill McClanahan; Brent McKenzie; Melanie A Kleinschek; Alex Owyang; Jeanine Mattson; Wendy Blumenschein; Erin Murphy; Manjiri Sathe; Daniel J Cua; Robert A Kastelein; Donna Rennick
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

5.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

6.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Authors:  Marcin Kortylewski; Hong Xin; Maciej Kujawski; Heehyoung Lee; Yong Liu; Timothy Harris; Charles Drake; Drew Pardoll; Hua Yu
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

Review 7.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

8.  Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation.

Authors:  Phyllis F Y Cheung; Chun K Wong; Christopher W K Lam
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

Review 9.  Interleukin-23/Th17 pathways and inflammatory bowel disease.

Authors:  Clara Abraham; Judy Cho
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

10.  Interleukin-23 drives innate and T cell-mediated intestinal inflammation.

Authors:  Sophie Hue; Philip Ahern; Sofia Buonocore; Marika C Kullberg; Daniel J Cua; Brent S McKenzie; Fiona Powrie; Kevin J Maloy
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

View more
  10 in total

Review 1.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

2.  Elevated proinflammatory cytokine IL-17A in the adjacent tissues along the adenoma-carcinoma sequence.

Authors:  Guanglin Cui; Hang Yang; Jianbo Zhao; Aping Yuan; Jon Florholmen
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

3.  Significant association between interleukin-17A polymorphism and colorectal cancer.

Authors:  Inés Omrane; Raja Marrakchi; Olfa Baroudi; Amel Mezlini; Hager Ayari; Imen Medimegh; Nejla Stambouli; Nadia Kourda; Hassen Bouzaienne; Nancy Uhrhammer; Karim Bougatef; Yves-Jean Jean Bignon; Amel Benammar-Elgaaied
Journal:  Tumour Biol       Date:  2014-04-04

4.  IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer.

Authors:  Anne-Marie Baird; Eilis Dockry; Anne Daly; Emma Stack; Derek G Doherty; Kenneth J O'Byrne; Steven G Gray
Journal:  Front Oncol       Date:  2013-06-19       Impact factor: 6.244

5.  Involvement of IL17A, IL17F and IL23R Polymorphisms in Colorectal Cancer Therapy.

Authors:  Inés Omrane; Imen Medimegh; Olfa Baroudi; Hager Ayari; Walid Bedhiafi; Nejla Stambouli; Marwa Ferchichi; Nadia Kourda; Yves-Jean Bignon; Nancy Uhrhammer; Amel Mezlini; Karim Bougatef; Amel Benammar-Elgaaied
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

6.  Interleukin-23 Facilitates Thyroid Cancer Cell Migration and Invasion by Inhibiting SOCS4 Expression via MicroRNA-25.

Authors:  Zhidan Mei; Shiming Chen; Chen Chen; Bokui Xiao; Fen Li; Yongping Wang; Zezhang Tao
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

Review 7.  Self-renewal molecular mechanisms of colorectal cancer stem cells.

Authors:  Tianhui Pan; Jinghong Xu; Yongliang Zhu
Journal:  Int J Mol Med       Date:  2016-11-30       Impact factor: 4.101

Review 8.  Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?

Authors:  Elizabeth N Ergen; Nabiha Yusuf
Journal:  Exp Dermatol       Date:  2018-07       Impact factor: 3.960

9.  Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis.

Authors:  Jillian L Pope; Rizwan Ahmad; Ajaz A Bhat; Mary K Washington; Amar B Singh; Punita Dhawan
Journal:  Mol Cancer       Date:  2014-07-06       Impact factor: 27.401

10.  Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation.

Authors:  Anna Malecka; Qunwei Wang; Sabaria Shah; Ruhcha V Sutavani; Ian Spendlove; Judith M Ramage; Julie Greensmith; Hester A Franks; Michael J Gough; Anja Saalbach; Poulam M Patel; Andrew M Jackson
Journal:  J Leukoc Biol       Date:  2016-04-05       Impact factor: 4.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.